These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 2837440

  • 1. [Quinolones: significance and problems in the clinic and in general practice].
    Daschner F, Kappstein I.
    Internist (Berl); 1988 Mar; 29(3):206-12. PubMed ID: 2837440
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Quinolones. Gyrase inhibitors].
    Höffler D.
    Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
    [No Abstract] [Full Text] [Related]

  • 5. [Possible development of resistance to quinolones. Its significance for general practice].
    Mohr CP.
    Fortschr Med; 1988 Mar 30; 106(9):181-4. PubMed ID: 3286434
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Intensified risk monitoring of new drugs in general practice by the established physician].
    Hanpft R, Hannig M.
    Verh Dtsch Ges Inn Med; 1989 Mar 30; 95():675-82. PubMed ID: 2574924
    [No Abstract] [Full Text] [Related]

  • 9. [Bacterial internalization and intracellular activity of quinolones and macrolides].
    Bellussi L, De Benedetto M, Lauriello M, Passali GC, Passali D.
    Acta Otorhinolaryngol Ital; 2007 Apr 30; 27(2 Suppl 87):1-11. PubMed ID: 17702375
    [No Abstract] [Full Text] [Related]

  • 10. [The aminoglycosides].
    Marre R, Schulz E, Sack K.
    Internist (Berl); 1989 Jan 30; 30(1):13-9. PubMed ID: 2646235
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [How can we protect against broad-band pathogens? The situation with quinolone resistance].
    Kresken M, Hafner D.
    Pharm Unserer Zeit; 2001 Jan 30; 30(5):436-45. PubMed ID: 11575181
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Update on cross-resistance of fluoroquinolones.
    Garau J.
    Int J Clin Pract Suppl; 2000 Dec 30; (115):94-8. PubMed ID: 11219309
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Which partner for the betalactam agent in empirical combined therapy? II. Aminoglycoside].
    Mimoz O, Grollier G.
    Ann Fr Anesth Reanim; 2004 Jun 30; 23(6):639-42. PubMed ID: 15234735
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effective antimicrobial therapy: an approach for physicians and community hospitals.
    Bryan CS, Ervin FR, John JF, Richards VR.
    J S C Med Assoc; 1986 Mar 30; 82(3):121-248. PubMed ID: 3084868
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.